Information Provided By:
Fly News Breaks for August 4, 2015
REGN
Aug 4, 2015 | 12:06 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Regeneron Pharmaceuticals to $607 following the company's "strong" Q2 results. He keeps a Neutral rating on the name.